pyrazines has been researched along with Diarrhea in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 19 (70.37) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
| Authors | Studies |
|---|---|
| Lamanna, N; Lipsky, A | 1 |
| Kaur, V; Swami, A | 1 |
| Channick, R; Chin, K; Coghlan, JG; Di Scala, L; Gaine, S; Galiè, N; Ghofrani, HA; Hoeper, MM; Lang, IM; McLaughlin, V; Preiss, R; Rubin, LJ; Simonneau, G; Sitbon, O; Tapson, VF | 1 |
| Atkinson, C; Breuer, J; Brown, LK; Burns, SO; Goldstein, R; Jacobs, M; Lowe, DM; Roy, S; Ruis, C; Williams, R; Yara-Romero, E | 1 |
| Aerts, JGJV; Baas, P; Cedrés, S; Fennell, DA; Gilligan, D; Kindler, H; Nakano, T; Nolan, L; Nowak, AK; Pachter, JA; Pavlakis, N; Scherpereel, A; Taylor, P; van Meerbeeck, JP; Weaver, DT | 1 |
| Awan, FT; Bibikova, E; Brown, JR; Byrd, JC; Charuworn, P; Frigault, MM; Furman, RR; Hamdy, A; Hillmen, P; Izumi, R; Linghu, B; Pagel, JM; Patel, P; Schuh, A; Stephens, DM; Wang, MH; Woyach, J | 1 |
| Czimmer, J; Hoffman, DC; Kehne, J; Luckey, A; Maynard, GD; Million, M; Taché, Y; Zhao, JF | 1 |
| Comenzo, R; Cossor, F; Fallo, S; Kaul, E; Klein, A; Miller, K; Shah, G; Smith, H; Sprague, K | 1 |
| Al-Shurbaji, A; Denison, H; Eriksson, JW; Himmelmann, A; Knutsson, M; Löfgren, L; Mårtensson, G; Nilsson, C; Tornqvist, H | 1 |
| Hong, D; Wu, B; Xiao, Y; Zhao, Q; Zheng, D | 1 |
| Awan, FT; Barrientos, JC; Brown, JR; Byrd, JC; Chaves, J; Covey, T; Devereux, S; Diacovo, TG; Fardis, M; Furman, RR; Ghia, P; Hamdy, A; Harrington, B; Hillmen, P; Huang, J; Izumi, R; Johnson, AJ; Johnson, D; Jones, JA; Kaptein, A; Lannutti, BJ; McGreivy, J; O'Brien, S; Pagel, JM; Rothbaum, W; Schuh, A; Stephens, DM; Wang, X; Wierda, WG; Woyach, J | 1 |
| Byrd, JC; Coombes, KR; Coss, CC; Covey, T; Gardner, HL; Gulrajani, M; Hamdy, A; Harrington, BK; Izumi, R; Johnson, AJ; Kaptein, A; Kisseberth, WC; Krejsa, C; London, CA; Rothbaum, W; Russell, DS; Urie, BK; Van Lith, B; Zhang, X | 1 |
| Bao, L; Huang, XJ; Lu, XJ; Zhang, XH | 1 |
| Chott, A; Formanek, M; Hauff, W; Jonak, C; Müllauer, L; Püspök, A; Raderer, M; Troch, M; Zielinski, CC | 1 |
| Alessandrino, EP; Barbarano, L; Bernasconi, P; Cafro, AM; Carella, AM; Corso, A; Grillo, G; Lazzarino, M; Mangiacavalli, S; Montalbetti, L; Morra, E; Pascutto, C; Spriano, M; Varettoni, M | 1 |
| Chen, C; Eckhardt, SG; Pugh, TJ; Raben, D; Rabinovitch, R; Rusthoven, KE; Swing, R | 1 |
| Cos Arregui, E; González Asanza, C; Huerta Madrigal, A; Menchén Fernández-Pacheco, P; Merino Rodriguez, B; Nogales Rincón, O | 1 |
| Alimena, G; Breccia, M; Cilloni, D; D'Auria, F; Gottardi, E; Latagliata, R; Mandelli, F; Musto, P; Saglio, G; Sanpaolo, G | 1 |
| Dumitrescu, O; Gerecitano, J; Hamlin, P; Horanlli, E; Iasonos, A; Mo, Q; Moskowitz, CH; Noy, A; O'Connor, OA; Pappanicholaou, J; Portlock, C; Rojas, CN; Sarasohn, D; Schulman, P; Straus, D; Zelenetz, AD; Zhang, Z | 1 |
| Aydin, F; Bayik, M; Firatli-Tuglular, T; Kaygusuz, I; Toptas, T; Uzay, A | 1 |
| Abonour, R; Anderson, KC; Bengoudifa, BR; Bourquelot, PM; de Magalhaes-Silverman, M; Goldschmidt, H; Hazell, K; Lonial, S; Matous, J; Siegel, D; Vij, R; Wolf, JL | 1 |
| Alba, M; Engel, SS; Goldstein, BJ; Guan, Y; Johnson-Levonas, AO; Kaufman, KD; Li, Z; Shentu, Y; Yang, W | 1 |
| Antolín, M; Guarner, F; Malagelada, JR; Medina, C; Radomski, A; Radomski, MW; Salas, A; Videla, S; Vilaseca, J | 1 |
| Anderson, K; Hideshima, T; Mitsiades, C; Richardson, PG | 1 |
| Adjei, AA; Alberti, D; Alberts, SR; Binger, K; Bruzek, L; Dy, GK; Erlichman, C; Hanson, LJ; Kaufmann, SH; Mandrekar, S; Marnocha, R; Pitot, HC; Thomas, JP; Tutsch, K; Wilding, G | 1 |
| Calderoni, A; Cornu, P; Freimann, H; Olie, R | 1 |
| Albanell, J; Awada, A; Baselga, J; Canney, PA; Cardoso, F; Dirix, LY; Gascon, P; Gil, T; Piccart, MJ | 1 |
4 review(s) available for pyrazines and Diarrhea
| Article | Year |
|---|---|
Managing toxicities of Bruton tyrosine kinase inhibitors.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Arrhythmias, Cardiac; Arthralgia; Benzamides; Diarrhea; Hemorrhage; Humans; Hypertension; Infection Control; Infections; Male; Piperidines; Protein Kinase Inhibitors; Pyrazines | 2020 |
Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Benzamides; Bridged Bicyclo Compounds, Heterocyclic; Diarrhea; Drug Resistance, Neoplasm; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Nausea; Piperidines; Protein-Tyrosine Kinases; Pyrazines; Pyrazoles; Pyrimidines; Signal Transduction; Sulfonamides | 2017 |
Risk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trials.
Topics: Diabetes Mellitus, Type 2; Diarrhea; Humans; Hypoglycemic Agents; Odds Ratio; Pyrazines; Randomized Controlled Trials as Topic; Risk Assessment; Sitagliptin Phosphate; Triazoles | 2014 |
Proteasome inhibition in hematologic malignancies.
Topics: Asthenia; Boronic Acids; Bortezomib; Cysteine Endopeptidases; Diarrhea; Hematologic Neoplasms; Humans; Multienzyme Complexes; Nausea; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Survival Analysis; Treatment Outcome | 2004 |
16 trial(s) available for pyrazines and Diarrhea
| Article | Year |
|---|---|
Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Diarrhea; Double-Blind Method; Drug Delivery Systems; Drug Therapy, Combination; Epoprostenol; Female; Headache; Humans; Hypertension, Pulmonary; Male; Middle Aged; Pyrazines; Signal Transduction | 2018 |
Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study.
Topics: Adult; Aged; Aged, 80 and over; Benzamides; Diarrhea; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mesothelioma; Mesothelioma, Malignant; Middle Aged; Nausea; Neurofibromin 2; Pleural Neoplasms; Pyrazines; Sulfonamides; Treatment Outcome | 2019 |
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Phosphorylation; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Pyrazines; Pyrazoles; Pyrimidines; Treatment Outcome | 2019 |
Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial.
Topics: Acetates; Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Diacylglycerol O-Acyltransferase; Diarrhea; Dose-Response Relationship, Drug; Gastric Emptying; Glucagon-Like Peptide 1; Humans; Intestinal Absorption; Male; Middle Aged; Obesity; Peptide YY; Pyrazines; Treatment Outcome; Weight Loss | 2014 |
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia.
Topics: Administration, Oral; Agammaglobulinaemia Tyrosine Kinase; Aged; Antineoplastic Agents; Benzamides; Chromosome Deletion; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Headache; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Recurrence | 2016 |
Preclinical Evaluation of the Novel BTK Inhibitor Acalabrutinib in Canine Models of B-Cell Non-Hodgkin Lymphoma.
Topics: Agammaglobulinaemia Tyrosine Kinase; Animals; Anorexia; Antineoplastic Agents; B-Lymphocytes; Benzamides; Cell Line, Tumor; Diarrhea; Disease Models, Animal; Disease-Free Survival; Dogs; Drug Administration Schedule; Drug Evaluation, Preclinical; Female; Humans; Lethargy; Lymphoma, Large B-Cell, Diffuse; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Vomiting; Weight Loss | 2016 |
[Effects of bortezomib at different doses in combination with dexamethasone in treatment of relapsed or refractory multiple myeloma: a comparative study].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dexamethasone; Diarrhea; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Follow-Up Studies; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Prospective Studies; Pyrazines; Treatment Outcome | 2008 |
A phase II study of bortezomib in patients with MALT lymphoma.
Topics: Adult; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Female; Follow-Up Studies; Humans; Lymphoma, B-Cell, Marginal Zone; Male; Middle Aged; Nausea; Nervous System Diseases; Pyrazines; Treatment Outcome | 2009 |
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Constipation; Cyclophosphamide; Dexamethasone; Diarrhea; Etoposide; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Infections; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Transplantation, Autologous; Treatment Outcome | 2010 |
Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Colorado; Combined Modality Therapy; Diarrhea; Dose Fractionation, Radiation; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; Infusions, Intravenous; Lymphopenia; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasms; Neutropenia; Palliative Care; Pyrazines; Radiography | 2010 |
Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes.
Topics: Adult; Aged; Aged, 80 and over; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Erythroid Cells; Female; Fever; Gene Expression; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Neutropenia; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Thrombocytopenia; Treatment Outcome; WT1 Proteins | 2011 |
Phase I trial of weekly and twice-weekly bortezomib with rituximab, cyclophosphamide, and prednisone in relapsed or refractory non-Hodgkin lymphoma.
Topics: Anemia; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Follow-Up Studies; Humans; Leukopenia; Lymphoma, Non-Hodgkin; Male; Middle Aged; Nausea; Prednisone; Pyrazines; Recurrence; Rituximab; Treatment Outcome | 2011 |
Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Lenalidomide; Male; Metabolic Clearance Rate; Middle Aged; Multiple Myeloma; Nausea; Neutropenia; Panobinostat; Pyrazines; Recurrence; Remission Induction; Thalidomide; Thrombocytopenia; Treatment Outcome | 2012 |
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
Topics: Abdominal Pain; Adult; Aged; Asian People; Blood Glucose; China; Diabetes Mellitus, Type 2; Diarrhea; Dipeptidyl-Peptidase IV Inhibitors; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrazines; Single-Blind Method; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2012 |
A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; bcl-2-Associated X Protein; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle Proteins; Cell Line, Tumor; Cyclin E; Cyclin-Dependent Kinase Inhibitor p27; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatigue; Female; Humans; I-kappa B Proteins; Male; Middle Aged; Nausea; Neoplasms; NF-kappa B; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Thrombocytopenia; Treatment Outcome; Tumor Suppressor Proteins; Vomiting | 2005 |
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study.
Topics: Adult; Aged; Alopecia; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Belgium; Boronic Acids; Bortezomib; Breast Neoplasms; Breast Neoplasms, Male; Diarrhea; Docetaxel; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; Pyrazines; Spain; Taxoids; Treatment Outcome; United Kingdom; Vomiting | 2008 |
7 other study(ies) available for pyrazines and Diarrhea
| Article | Year |
|---|---|
Mutagenesis in Norovirus in Response to Favipiravir Treatment.
Topics: Amides; Antiviral Agents; Caliciviridae Infections; Chronic Disease; Common Variable Immunodeficiency; Diarrhea; Fatal Outcome; Humans; Male; Middle Aged; Mutagenesis; Norovirus; Pyrazines | 2018 |
The newly developed CRF1-receptor antagonists, NGD 98-2 and NGD 9002, suppress acute stress-induced stimulation of colonic motor function and visceral hypersensitivity in rats.
Topics: Administration, Oral; Animals; Colon; Corticotropin-Releasing Hormone; Defecation; Diarrhea; Drug Antagonism; Hyperalgesia; Injections, Intraperitoneal; Injections, Intraventricular; Injections, Subcutaneous; Intubation, Gastrointestinal; Irritable Bowel Syndrome; Male; Molecular Structure; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Stress, Physiological; Viscera | 2013 |
Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients.
Topics: Aged; Aged, 80 and over; Amyloidosis; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Therapy, Combination; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Retrospective Studies; Thrombocytopenia | 2013 |
Rectal bleeding and diarrhea caused by bortezomib-induced colitis.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Colitis; Diarrhea; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Rectum | 2010 |
Bortezomib in patients with renal impairment.
Topics: Aged; Antineoplastic Agents; Boronic Acids; Bortezomib; Cytochrome P-450 Enzyme System; Diarrhea; Female; Humans; Male; Middle Aged; Multiple Myeloma; Pyrazines; Renal Insufficiency; Retrospective Studies; Survival Analysis | 2011 |
Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis.
Topics: Animals; Anticoagulants; Colitis, Ulcerative; Colon; Dextran Sulfate; Diarrhea; Disease Models, Animal; Gastrointestinal Hemorrhage; Hydroxamic Acids; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinase Inhibitors; Protease Inhibitors; Pyrazines; Rats; Rats, Sprague-Dawley; Sulfonamides | 2003 |
Daily practice use of Bortezomib in relapsed/refractory multiple myeloma. Safety/efficacy results of a compassionate use program in Switzerland.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boronic Acids; Bortezomib; Diarrhea; Drug Administration Schedule; Fatigue; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Pyrazines; Recurrence; Switzerland; Thrombocytopenia; Treatment Outcome | 2007 |